Immunotherapy or Targeted Therapy With or Without Stereotactic Radiosurgery for Patients With Brain Metastases From Melanoma or Non-small Cell Lung Cancer

Immunotherapy or Targeted Therapy With or Without Stereotactic Radiosurgery for Patients With Brain Metastases From Melanoma or Non-small Cell Lung Cancer is a phase 3, randomised interventional study registered as NCT05522660 by ETOP IBCSG Partners Foundation, with a registry enrolment figure of 180 participants, started 2022-11-30 and due to reach its primary completion in 2026-09. Interventions recorded: Stereotactic radiosurgery; Immune checkpoint inhibitor. Conditions listed: Non-Small Cell Lung Cancer; Melanoma. Primary outcome: CNS-specific PFS, locally assessed as per iRANO criteria. Lung eligibility wording from the registry: "* Primary disease of histologically confirmed (from primary tumour or from a metastatic lesion, including in the brain) melanoma or NSCLC". Sites: Italy, Netherlands, Spain, Switzerland, United Kingdom. United Kingdom sites listed: 2. No results are recorded here; the registry entry is the source.